Clinical Trial Update: GVAX® Vaccine for Prostate Cancer vs Docetaxel & Prednisone in Patients With Metastatic Hormone-Refractory Prostate Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial comparing GVAX Prostate Cancer Vaccine to docetaxel plus prednisone for metastatic hormone-refractory prostate cancer was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• GVAX Prostate Cancer Vaccine (GM-CSF expressing tumor cell vaccine)
• PREDNISONE (Prednisone)

Snippet

Sponsor: Cell Genesys | Conditions: Prostate Cancer | Phase 3 | Status: TERMINATED